Evidencia científica
Estudios revisados por pares sobre suplementación
Indexamos automáticamente los estudios más recientes publicados en PubMed (NCBI / US National Library of Medicine). Filtra por tema o explora la evidencia más reciente.
-
Ribósido de Nicotinamida
Age-Dependent Progression of Neurological Involvement in PRPP Deficiency: Insights from a Four-Generation Family and Systematic Review
Biomolecules · 2026
median symptomatic delay was 3 years (range up to 19). We posit that this temporal dissociation reflects differential tissue vulnerability to intracellular ATP/GTP and NAD+ depletion…
-
Ribósido de Nicotinamida
Does nicotinamide riboside supplementation increase milk production in postpartum women with infants admitted to a neonatal intensive care unit? Protocol for the MOONRISE randomised, double-blind, placebo-controlled pilot feasibility trial
BMJ open · 2026
INTRODUCCIÓN: Un suministro adecuado de la propia leche materna desempeña un papel crítico en la optimización de los resultados de salud para los lactantes hospitalizados en…
-
Ribósido de Nicotinamida
Safety and efficacy of individualised exercise and NAD(+) precursor supplementation in patients with Friedreich’s ataxia in the USA: a single-centre, 2 × 2 factorial, randomised controlled trial
The Lancet. Neurology · 2026
BACKGROUND: Friedreich’s ataxia is a rare, chronic, progressive, neurodegenerative condition affecting multiple organ systems, including neurological, musculoskeletal, cardiac, and endocrine systems, and is marked by low…
-
Ribósido de Nicotinamida
LRRK2-targeting antisense oligonucleotide in Parkinson’s disease: a phase 1 randomized controlled trial
Nature medicine · 2026
and not dose limiting. No serious adverse events related to BIIB094 were reported in either part A or B. Systemic BIIB094 exposure increased with dose. Cerebrospinal…
-
Ribósido de Nicotinamida
NAD⁺ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence
Ageing research reviews · 2026
nonrandomized intravenous NMN study met inclusion criteria and primarily contributed short-term safety and biomarker information. An intravenous NAD⁺ pharmacokinetic pilot lacking eligible clinical outcomes was identified…
-
Ribósido de Nicotinamida
The differential impact of three different NAD(+) boosters on circulatory NAD and microbial metabolism in humans
Nature metabolism · 2026
results indicate a dual effect of NR and NMN and their microbially produced metabolite NA: a sustained increase in systemic NAD+ levels and a potent modulator…
